CYTK
Cytokinetics·NASDAQ
--
--(--)
--
--(--)
4.52 / 10
Netural
With a fund flow rating of 7.68/10, the stock shows robust fund flow characteristics. Supportive momentum from overall, block, and Extra-large trends is partially offset by concerning Small, Medium, and Large patterns, pointing to positive capital flow trajectory. Professional analyst opinion suggests overwhelmingly bullish analyst consensus, showing strong conviction.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
40%
Buy
60%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionBarclays
Times predicted6
Historical Win Rate0.0%
What is the analyst consensus for CYTK?
- CYTK holds a Bearish analyst rating, with 60% of experts assigning a Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.52/10 (Netural).
